Instituto de Investigación Sanitaria Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2024

  1. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)

    Gut Microbes, Vol. 16, Núm. 1

  2. Curcumin encapsulated in milk small extracellular vesicles as a nanotherapeutic alternative in experimental chronic liver disease

    Biomedicine and Pharmacotherapy, Vol. 173

  3. Fecal microbiota transplantation from female donors restores gut permeability and reduces liver injury and inflammation in middle-aged male mice exposed to alcohol

    Frontiers in Nutrition, Vol. 11

  4. Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

    Redox Biology, Vol. 71

  5. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

    Pharmacological Research, Vol. 200

  6. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of Ppp2r5d

    Cancers, Vol. 15, Núm. 16

  2. Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism

    Gut

  3. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling

    JHEP Reports, Vol. 5, Núm. 11

  4. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

  5. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  6. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis

    Gastroenterologia y Hepatologia

  7. Obesity under the moonlight of c-MYC

    Frontiers in Cell and Developmental Biology, Vol. 11

  8. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

    Liver International, Vol. 43, Núm. 9, pp. 1909-1919

  9. Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

2022

  1. A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver

    Metabolites, Vol. 12, Núm. 2

  2. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

    Cancers, Vol. 14, Núm. 1

  3. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  4. Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets

    Frontiers in Pharmacology

  5. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143